奥美拉唑联合伊托必利治疗功能性消化不良的有效性和安全性探讨

Investigation on the efficacy and safety of omeprazole combined itopride in the treatment of functional dyspepsia

目的探讨奥美拉唑联合伊托必利治疗功能性消化不良的临床疗效，并评价其安全性。方法功能性消化不良（FD）患者246例，按入院顺序随机分为三组，A组82例，口服奥美拉唑20mg，2次／d；B组82例，口服伊托必利50mg，3次／d；C组82例，口服奥美拉唑和伊托必利联合治疗，用法同上，三组均治疗4周。治疗结束后观察三组的症状改善情况和临床疗效，并评价安全性。结果C组改善早饱和餐后饱胀症状的有效率显著高于A组（95．1％、95．3％与64．6％、63．6％），C组改善上腹痛和上腹烧灼感症状的有效率显著高于B组（93．1％、90．8％与67．2％、65．1％），C组治疗的总有效率显著高于A组和B组（分别为91．5％、69．5％、73．2％），差异均有统计学意义（均P〈0．05）。结论奥美拉唑联合伊托必利治疗FD临床疗效确切，安全可靠，值得临床推广和普及。

Objective To study the effect of omeprazole combined itopride in treatment of functional dyspep- sia and the safety. Methods 246 patients with functional dyspepsia were randomly divided into three groups, each group of 82 cases. Group A was treated with omeprazole,20mg each time, twice every day. Group B was treated with itopride,50mg each time ,three times every day. Group C was treated with omeprazole combined itopride. All groups were treated for four weeks. Improvement of symptoms, clinical curative effect and safety were observed. Results The effective rate of early enough and after dinner full bilge symptoms of group C were 95.1% and 95.3 % , which were significantly higher than 64.6% and 63.6% of group A. The effective rate of abdominal pain and epigastric voiding symptoms of group C were 93.1% and 90.8% ,whieh were significantly higher than 67.2% and 65.1% of group B. The total effective rate of group C was 91.5%. ,which was significantly higher than 69.5% of group A and 73.2% of group B. All differences were statistically significant （ P 〈 0.05 ）. Conclusion Omeprazole combined itopride in treatment of functional dyspepsia has definite curative effect, which is safety and worth of clinical promotion and popu- larization.